Companies › EyeBiotech
2 active drug programs in 5 registered trials: 5 Phase 2; Ophthalmology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Remigromig (EYE103) humanized antibody | – | Phase 2 | Diabetic Macular Edema (DME); Neovascular Age-Related Macular Degeneration (NVAMD) | Jan 2027 |
| Tiespectus (EYE201/MK-8748) | – | Phase 2 | Macular Degeneration | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06957080 | Remigromig (EYE103) | Phase 2 | Diabetic Macular Edema (DME) | Ophthalmology | Jan 2027 |
| NCT06571045 | Remigromig (EYE103) | Phase 2 | Diabetic Macular Edema (DME) | Ophthalmology | Dec 2027 |
| NCT07205887 | Remigromig (EYE103) | Phase 2 | Neovascular Age-Related Macular Degeneration (NVAMD) | Ophthalmology | Jun 2028 |
| NCT07440225 | Tiespectus (EYE201/MK-8748) | Phase 2 | Macular Degeneration | Ophthalmology | Jun 2028 |
| NCT07496567 | Tiespectus (EYE201/MK-8748) | Phase 2 | Macular Degeneration | Ophthalmology | Jul 2028 |
No annotated target.
–
AiViva BioPharma Adverum Biotechnologies BioDlink Biopharm EyePoint Pharmaceuticals Intra-IMMUSG Pte
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.